Atea’s antiviral treatment combo works for 98% of HCV patients
Note: This story was updated Aug. 22, 2024, to clarify the timeline detailing the results of treatment. Atea Pharmaceuticals’ once-daily oral antiviral treatment for…
Steve Bryson, PhD, Science Writer — 
Articles by Steve Bryson
Small amounts of alcohol deemed OK in early steatotic liver disease
Drinking a small amount of alcohol each day did not raise the mortality risk among people in the early stages of steatotic liver disease…
Gut microbiota may be noninvasive diagnostic tool in biliary atresia
The composition of microbes is altered in the intestines of infants with biliary atresia, a type of liver disease that affects the bile ducts,…
Resmetirom successfully treats NASH, reduces liver scarring in trial
One year of daily resmetirom, Madrigal Pharmaceuticals’ investigational oral therapy, was shown to successfully treat nonalcoholic steatohepatitis (NASH), a severe type of fatty liver…
FDA to review approval application for seladelpar as PBC treatment
The U.S. Food and Drug Administration (FDA) will review CymaBay Therapeutics’ application for seladelpar, an oral investigational treatment for adults with…
